How it works:
Mitomycin functions as an alkylating agent that inhibits DNA synthesis in tumour cells, leading to cell cycle arrest and apoptosis. It is used in systemic chemotherapy and locally (e.g. intravesically) for bladder cancer. Its cytotoxic action is selective for rapidly dividing cancer cells.
Who should use it:
Patients with gastric or pancreatic cancer
Individuals undergoing bladder cancer treatment
As part of combination chemotherapy regimens
After assessment of liver, kidney and haematologic function
Gastric cancer
Pancreatic cancer
Cervical cancer
Breast cancer
Superficial bladder cancer (local use)
MITOMYCIN is administered intravenously or intravesically under medical supervision. Dosage and duration depend on tumour type, treatment protocol and patient condition. Close monitoring is required during therapy.
Hypersensitivity to mitomycin
Severe bone marrow suppression
Active infections
Pregnancy and breastfeeding
Renal or hepatic failure
Bone marrow suppression (anaemia, leukopenia, thrombocytopenia)
Nausea and vomiting
Mucosal damage
Nephrotoxicity
Pulmonary fibrosis or pneumonitis
Injection site reactions
